How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers

Háskóli ÍslandsUniversity of IcelandChatzidionysiou, KaterinaDelcoigne, BénédicteFrisell, ThomasHetland, Merete LGlintborg, Bentedreyer, leneCordtz, RenéZobbe, KristianNordström, DanTrokovic, NinaAaltonen, KalleProvan, Sella AarrestadGröndal, GerðurGudbjornsson, BjornAskling, Johan2020-11-132020-11-132020-09-08Chatzidionysiou K, Delcoigne B, Frisell T, et alHow do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registersRMD Open 2020;6:e001363. doi: 10.1136/rmdopen-2020-0013632056-5933https://hdl.handle.net/20.500.11815/2202Publisher's version (útgefin grein)[No abstract available]e001363eninfo:eu-repo/semantics/openAccessArthritisBiological TherapyEpidemiologyRheumatoidIktsýkiLíftæknilyfHow do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registersinfo:eu-repo/semantics/articleRMD Open10.1136/rmdopen-2020-001363